Nation
World
Politics
Sports
Business
Entertainment
Life
Tech
Science
Opinion
Crime
Health
Oddities

404

Not found

This newslink doesn't exist or it was removed.

Go to Homempage.

Sugerencias de la Hemeroteca

Depression symptoms eased within a week using TMS magnet therapy: new study

New York Post USA Life November 21, 2023

thumbnailUsing magnets to treat depression sounds like a mad scientist’s scheme — but it actually works. The treatment — known as — is backed up by years of research and is approved by the Food and Drug Administration. It’s a completely noninvasive therapy that delivers... + más

Top 5 Transportation Technology Trends For 2023 | Forbes

Ukrainian war veterans with amputated limbs find freedom in the practice of jiu-jitsu | WPLG Local 10


Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity

Forbes USA Business October 15, 2022

thumbnailGetty Images Key Takeaways You may have heard the overwhelmingly positive news for Biogen lately—this stock has been a rare winner during a time of extreme volatility in the stock market due to consistent rate hikes. Biogen Inc. (BIBB) is one of the older global biotech... + más

Biogen to pay $900M to settle allegations of improper physician kickbacks | Fox Business

Biogen to pay $900 million to settle allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs | CNBC


GoldenEye 007 is finally coming to Xbox and Nintendo Switch

The Verge USA Entertainment September 24, 2022

thumbnailGoldenEye 007 is finally coming to Xbox and Nintendo SwitchGoldenEye 007 is finally coming to Xbox and Nintendo Switch / After years of rights issues, a GoldenEye 007 remaster is herep>span:first-child]:text-black text-blurple>By / Sep 13, 2022, 2:30 PM UTC Share this... + más

GoldenEye 007 re-release finally confirmed—but it’s not the leaked remake [Updated] | Ars Technica

Why does Logitech have a white Xbox Series X? (Because they put a skin on it.) | The Verge


Biogen Ends Development of Alzheimer’s Drug Aduhelm

MarketWatch USA Business January 31, 2024

thumbnailThe Aduhelm commercial program had been all but dead since 2022, when the Centers for Medicare & Medicaid Services (CMS) declined to offer Medicare coverage for the drug. Biogen had been continuing of Aduhelm, however, as a condition of the Food and Drug Administration’s... + más

Biogen Ends Development of Alzheimer’s Drug Aduhelm | MarketWatch

Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity | Forbes


Biogen Ends Development of Alzheimer’s Drug Aduhelm

MarketWatch USA Business January 31, 2024

thumbnailThe Aduhelm commercial program had been all but dead since 2022, when the Centers for Medicare & Medicaid Services (CMS) declined to offer Medicare coverage for the drug. Biogen had been continuing of Aduhelm, however, as a condition of the Food and Drug Administration’s... + más

Biogen Ends Development of Alzheimer’s Drug Aduhelm | MarketWatch

Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity | Forbes



About iurex | Privacy Policy | Disclaimer |